Gary Gilkeson to Complement Inactivating Agents
This is a "connection" page, showing publications Gary Gilkeson has written about Complement Inactivating Agents.
Connection Strength
0.237
-
The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice. Arthritis Rheum. 2011 Apr; 63(4):1076-85.
Score: 0.088
-
A targeted inhibitor of the complement alternative pathway reduces RPE injury and angiogenesis in models of age-related macular degeneration. Adv Exp Med Biol. 2010; 703:137-49.
Score: 0.080
-
Association of reactive oxygen and nitrogen intermediate and complement levels with apoptosis of peripheral blood mononuclear cells in lupus patients. Arthritis Rheum. 2007 Nov; 56(11):3738-47.
Score: 0.069